Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.58 (-2.01%)
Updated May 28, 2024 04:01 PM ET
After-Market: $28.33 +0.03 (0.11%) 5:12 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
PFE 28.30 -0.58(-2.01%)
Will PFE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Pfizer (PFE) Recently Broke Out Above the 200-Day Moving Average
Other News for PFE
Gilead Sciences: Seriously Undervalued At Peak Pessimism
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Event-Driven Strategies, Commodities, And Writing Options With Asif Suria
Revenge of the Apes: 3 Reddit WallStreetBets Stocks That Could Pop Next
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,